不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>公司动态>Vaccinex, Inc. 启动晚期实体瘤癌症患者创新治疗用抗体的临床试验

Vaccinex, Inc. 启动晚期实体瘤癌症患者创新治疗用抗体的临床试验

Vaccinex2011年2月17日 10:59 点击:1100


 美国Vaccinex  美国食品药品监督管理局(FDA,U.S. Food and Drug Administration) 
 

 

NIUYUEZHOULUOCHESITE2011NIAN1YUE4RIDIAN /MEITONGSHEYAZHOU/ -- Vaccinex, Inc. JINTIANXUANBUGAIGONGSIYIJINGHUODELEMEIGUOSHIPINYAOWUGUANLIJU (FDA) DEXUKE,JIANGQIDONGYIQILINCHUANGSHIYANLAIPINGGUHOUXUANZHILIAOYONGKANGTI VX15/2503 ZAIWANQISHITIZHONGLIUAIZHENGHUANZHEZHONGDEANQUANXING、NAISHOUXING、YAOWUDAIXIEHEYAOXIAOQINGKUANG。

(TUBIAO:)

不用本金就能赚钱的方法VX15/2503 SHIYIZHONGRENXINGHUADEXINYINGKANGTI,NENGZUZHI semaphorin 4D(DAOXIANGDANBAI4D,JIANCHENGSEMA4D)DEHUODONG。GAIGONGSIYUQIJINNIANJIANGQIDONGLIANGZHONGZHILIAOYONGKANGTIDELINCHUANGSHIYAN,SEMA4D BIANSHIQIZHONGDIYIZHONG。Vaccinex GAOJIFUZONGCAIJIANSHOUXIYUNYINGGUAN Ray Watkins BIAOSHI:“DUI Vaccinex ERYAN,ZAIKAIFADELINCHUANGJIEDUANZHONGTUIJIN VX15DESHIYONGSHIGELINGRENZHENFENDECHENGJIU,YEZHENGMINGLEWOMENYANFATUANDUIDEFENGFUJINGYANHEZHUOYUECAINENG。”

不用本金就能赚钱的方法Vaccinex ZONGCAIJIANSHOUXIZHIXINGGUAN Maurice Zauderer BOSHISHUO:“SEMA4D SHIGEZHENFENRENXINDEZHILIAOBABIAO,JUYOUYUJIZHONGJIBINGGUOCHENGXIANGDUIYINGDECHUSESHENGWUXINGNENG。ZHENGRUQIMINGCHENGSUOTIXIANDENEIYANG,semaphorin FENZIYINDAOBUTONGLEIXINGDEXIBAOYIBUTONGFANGSHIJINXINGHUODONGHEYUNZHUAN。LIRU,SEMA4D HUICUJINZHONGLIUXIBAOXIANGXINWEIZHIDEZHUANYI,BINGBANGZHUSHENGCHENGXIBAO,XINGCHENGWEIZHONGLIUTIGONGYINGYANGHENENGLIANGSUOBIXUDEXINXUEGUAN。YUJITONGGUOZUZHIZHEIYIXINHAO,FAN SEMA4D KANGTI () JIANGBUJINNENGYIZHIYUANFAXINGZHONGLIUDESHENGZHANG,YENENGXIANZHIXIANGXINWEIZHIDEZHUANYI。”Zauderer BOSHIBIAOSHI:“ZHEIYIDIANHENZHONGYAO,YINWEIRUGUOZHONGLIUBUZHUANYI,YISHIJIUNENGZHIYUAIZHENG。”ZAIQITAZUZHIHEJIBINGGUOCHENGZHONG,LIRUDUOFAXINGYINGHUAZHENG (MS) DENGTUOSUIQIAOBINGZHONGDESHENJINGXIBAOSUNHUAI,TONGYANGDE semaphorin DUIXIBAODESHENGZHANGQUEYOUFANXIAOGUO,HUIZUZHISHOUSUNSHENJINGYUANDEZAISHENGHESUIQIAOZAISHENG。GUANYUZHEIZHONGQINGKUANG,Zauderer BOSHISHUO:“VX15/2503 KANGTIYOUKENENGCHENGWEIZHILIAODUOFAXINGYINGHUAZHENGDEGEMINGXINGXINLIAOFA (),TAJIKEYIZUOWEIKANGYANYAOZUZHIJIBINGFAZHAN,HAINENGCUJINSHOUSUNZUZHIDEYUHE。”Vaccinex JIHUAZAIJINNIANWANXIESHIHOUZHENDUIDUOFAXINGYINGHUAZHENGKAISHI VX15/2503 DEERQISHIYAN。

Vaccinex (), Inc. 简介

Vaccinex, Inc. CHUANGLIYU1997NIAN,WEIYUNIUYUEZHOULUOQIESITE,SHIYIJIAFEIGONGKAISHANGSHIDESHENGWUKEJIGONGSI,ZHILIYURENLEIZHILIAOYONGDANKELONGKANGTIHEYIMIAODEFAXIANHEKAIFA,ZHIZAIZHILIAOXUQIUDEBUDAOMANZUDEYANZHONGJIBING。WANGZHI:。

MEITILIANXIREN:

首席运营官 Raymond E. Watkins
电话:+1-585-271-2700 转105
电邮:rwatkins@vaccinex.com

 

消息来源 Vaccinex, Inc.


 

Rochester, NY - January 4, 2011.  Vaccinex, Inc. announced today that it has received clearance from FDA and will initiate a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody candidate VX15/2503 in cancer patients with advanced solid tumors.

不用本金就能赚钱的方法VX15/2503 is a novel humanized antibody that blocks the activity of semaphorin 4D (SEMA4D). It is the first of two of the Company’s therapeutic antibodies expected to begin clinical trials this year. “Advancing VX15 into the clinical stage of development is an exciting achievement for Vaccinex, and a testament to the experience and outstanding capabilities of our research and development teams,” said Ray Watkins, Senior Vice President and Chief Operating Officer of the company.

“SEMA4D is an exciting therapeutic target with remarkable biological properties relevant to several disease processes,” said Dr. Maurice Zauderer, President and Chief Executive Officer of Vaccinex. As reflected in its name, semaphorin, the molecule guides the activation and movement of different cell types in different ways. For example, SEMA4D promotes migration of tumor cells that metastasize to new locations as well as the outgrowth of cells that form new blood vessels required to provide nutrients and energy to tumors. It is anticipated that, by blocking this signal, the will both inhibit the growth of primary tumors and limit metastases to new sites. “This is important,” Dr. Zauderer said, “because if tumors did not metastasize, then surgeons could cure cancer.” In other tissues and disease processes, for example damage to neurons in demyelinating diseases such as multiple sclerosis (MS), the same semaphorin has an opposite effect on outgrowth of cells, preventing the regeneration and remyelination of damaged neurons. In this case, Dr. Zauderer said, “The VX15/2503 antibody has the potential to be a radical , acting both as an anti-inflammatory to protect against disease progression but also promoting healing of damaged tissue.” Vaccinex plans to initiate a second trial of VX15/2503 for MS later this year.

About Vaccinex, Inc.

Founded in 1997 and located in Rochester, NY, Vaccinex, Inc. is a privately held biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and vaccines to treat serious diseases with unmet needs. http://www.vaccinex.com/.

Press Contact

Raymond E. Watkins, Chief Operating Officer, 585.271.2700 (x-105)
e-mail: rwatkins@vaccinex.com
 

(来源: Vaccinex )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com

不用本金就能赚钱的方法 BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图